Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) EPS (Basic) (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of EPS (Basic) data on record, last reported at -$0.33 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 26.92% year-over-year to -$0.33; the TTM value through Sep 2025 reached $0.32, up 117.88%, while the annual FY2024 figure was -$0.98, 62.74% up from the prior year.
  • EPS (Basic) reached -$0.33 in Q3 2025 per GLUE's latest filing, down from -$0.15 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.57 in Q1 2025 and bottomed at -$0.71 in Q2 2023.
  • Average EPS (Basic) over 3 years is -$0.32, with a median of -$0.43 recorded in 2024.
  • The widest YoY moves for EPS (Basic): up 207.55% in 2025, down 26.92% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$0.57 in 2023, then soared by 140.35% to $0.23 in 2024, then plummeted by 243.48% to -$0.33 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.33 in Q3 2025, -$0.15 in Q2 2025, and $0.57 in Q1 2025.